Mepolizumab reduces asthma exacerbations among real-world patients with severe asthma and an eosinophilic phenotype.

GSK plc has announced that the China National Medical Products Administration has accepted for review the new drug ...

China NMPA accepts for review GSK’s Nucala NDA to treat patients with chronic obstructive pulmonary disease: London, UK Friday, February 21, 2025, 09:00 Hrs [IST] GSK plc announ ...

The National Pharmaceutical Pricing Authority directs pharma firms to revise the MRP of medicines following customs duty ...

GSK PLC on Thursday said its monoclonal antibody Nucala, also known as mepolizumab, has been accepted for review in China. The London-based pharmaceutical company said the China Medical Products ...

Asthma a chronic respiratory condition may be driven by specific immune cells that influence inflammation and severity ...

Products Administration has accepted for review the new drug application for Nucala (mepolizumab) as an add-on treatment for chronic obstructive pulmonary disease (COPD) with an eosinophilic ...

These medications, which include dupilumab (Dupixent), mepolizumab (Nucala), and omalizumab (Xolair), target a protein involved in the disease process, thereby reducing inflammation and the size ...

GSK's IL-5 inhibitor Nucala (mepolizumab) could also be heading for approval in COPD – at the second attempt – after reducing exacerbations in the phase 3 MATINEE trial, while Amgen and ...

If approved for marketing, it would be a companion and successor to Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma and various other indications that made sales of ...

Two recent well-designed randomised controlled trials have investigated the safety and efficacy of selected IL5 inhibition with mepolizumab (monoclonal antibody against IL5) in a subset of patients ...